MedTrace Logo

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers

NCT05874167 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-05-24

No results posted yet for this study

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6013 and each component in healthy adult volunteers in fast condition.

Conditions

  • Healthy Subjects

Interventions

DRUG

DW6013

Drug: DW6013 Single oral administration of DW6013 after an overnight fast Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast

Sponsors & Collaborators

  • Dong Wha Pharmaceutical Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2022-10-11
Completion
2022-10-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05874167 on ClinicalTrials.gov